Article Details
Retrieved on: 2025-04-25 22:18:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
BioNTech augmented its bispecific antibody cancer platform last fall when it acquired Biotheus for $800 million, which currently has a late-stage ...
Article found on: www.mitrade.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here